PALISADE BIO INC
For the period ended Jun 30, 2024. Filed Aug 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 12, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except share and per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| License revenue | $— | $— | $— | $250 |
| Operating expenses: | ||||
| Research and development | 2,628 | 2,177 | 4,842 | 3,418 |
| General and administrative | 1,583 | 1,432 | 3,042 | 2,970 |
| Total operating expenses | 4,211 | 3,609 | 7,884 | 6,388 |
| Loss from operations | (4,211) | (3,609) | (7,884) | (6,138) |
| Other (expense) income: | ||||
| Interest expense | (2) | (3) | (3) | (3) |
| Other income, net | 133 | 219 | 280 | 408 |
| Total other income, net | 131 | 216 | 277 | 405 |
| Net loss | $(4,080) | $(3,393) | $(7,607) | $(5,733) |
| Basic and diluted weighted average shares used in computing basic and diluted net loss per common share* | 1,228,453 | 427,862 | 1,000,367 | 357,572 |
| Basic and diluted net loss per common share* | $(3.32) | $(7.93) | $(7.60) | $(16.03) |
(*) Basic and diluted loss per common share and basic and diluted weighted average share used in computing basic and diluted loss per common share for thethree and six months ended June 30, 2023 has been adjusted to reflect the 1-for-15 reverse stock split effected on April 5, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.